How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

795 results for

Cutaneous Candidiasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

182. DuoResp Spiromax - budesonide / formoterol

of the 1 µg/kg acute dose but not the 10 µg/kg acute dose. These results suggested that tolerance to the anti-leakage effect of formoterol could occur with repeated higher doses (Bowden, 1997). The effects of formoterol on rat and guinea pig hypersensitivity reactions and on mouse IgE antibody formation were investigated. The inhibitory effect of intravenously and orally administered formoterol on (mouse) IgE-mediated 24-hour passive cutaneous anaphylaxis (PCA) in rats was 6.3 and 33 times

2014 European Medicines Agency - EPARs

185. BiResp Spiromax (budesonide / formoterol fumarate dihydrate)

the effectiveness of the 1 µg/kg acute dose but not the 10 µg/kg acute dose. These results suggested that tolerance to the anti-leakage effect of formoterol could occur with repeated higher doses (Bowden, 1997). The effects of formoterol on rat and guinea pig hypersensitivity reactions and on mouse IgE antibody formation were investigated. The inhibitory effect of intravenously and orally administered formoterol on (mouse) IgE-mediated 24-hour passive cutaneous anaphylaxis (PCA) in rats was 6.3 and 33 times

2014 European Medicines Agency - EPARs

186. Isavuconazonium sulfate (BAL8557) (Cresemba)

: Patient with Incorrect Drug Administration, Trial 9766-CL-0104 21 Table 6: Patients Who Received an Excluded Concomitant Medication 22 Table 7: Sites Selected for GCP Inspections 23 Table 8: Summary of Phase 3 Trials 27 Table 9: Summary of Phase 2 Trials 28 Table 10: Summary of Phase 1 Studies 30 Table 11: Phase 2 Study 9766-CL-0101/ WSA-CS-001: Results Summary of Treatment of Esophageal Candidiasis 43 Table 12: Phase 2 Study 9766-CL-0102/WSA-CS-002: Results Summary of Prophylaxis in Neutropenic AML

2014 FDA - Drug Approval Package

187. Secukinumab (Cosentyx)

treatment periods. Infections related to Candida did appear to show a dose response as shown in section 7.5.1. All Candida infections on secukinumab were mild or moderate in severity. 4 cases of esophageal candidiasis were reported (1 on 150 mg and 3 on 300 mg). Two of these cases were mild and two were moderate in severity. All were managed successfully with antifungal treatment and did not result in any interruption or discontinuation of study treatment. There was 1 additional case of esophageal (...) tissue disorders (11.4%, 11.8% and10.8% vs. 5.5%). Notable differences between the rates seen for 300 mg and 150 mg doses were primarily for preferred terms in the infections and infestations SOC which showed: ? 5 to 6 fold increases for 300 mg for erysipelas, bacterial pharyngitis, bacterial infection ? 2 to 3 fold increases for 300 mg urinary tract infections, bacterial sinusitis, otitis media/ otitis media bacterial, bacterial skin infections, impetigo, oral candidiasis, vulvovaginal candidiasis

2014 FDA - Drug Approval Package

188. Treatment of peritoneal dialysis?associated fungal peritonitis

not impact pharmaokinetics of either drug. The KHA-CARI Guidelines – Caring for Australasians with Renal Impairment Peritonitis Treatment and Prophylaxis (February 2014) Page 33 Spectrum of activity of echinocandins Fungicidal activity against: ? Candida spp.: including triazole-resistant isolates ? Similar to each other in vitro activity against Candida spp. o micafungin and anidulafungin similar (MICs) and generally lower than the MIC of caspofungin ? Resistance to echinocandins low to date (...) but occasional reports of acquired resistance in Candida spp. Fungistatic activity against: ? Aspergillus spp. Inherently resistant fungi: ? Cryptococcus neoformans ? Trichosporon spp. ? Fusarium spp. ? Zygomycetes ? Scedosporium spp. ? Pseudoallescheria spp. ? Rhodotorula spp. Terbinafine ? Monitor for myelosuppression. Dosage adjustment for renal failure by GFR > 50 mL/min normal 10 to 50 mL/min 100% 48-hourly < 10 mL/min 100% 48-hourly Doses for dialysis HD as for GFR <10 mL/min, dose after dialysis CAPD

2014 KHA-CARI Guidelines

189. The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients

albicans, 55%; C parapsilosis, 13%; C krusei, 4%; C glabrata, 2%; and C tropicalis, 2%), and Aspergillus spp (9 pulmonary, 5 cutaneous, and 1 each central nervous system, sinus, mediastinal tumor, and unspeci?ed) caused 82%ofthemoldinfections.Theremaining4moldinfections were caused by Mucorales (n¼ 3) and Exserohilum species (n¼ 1). Infections caused by Trichosporon species (blood- stream), Trichophyton tonsurans (bloodstream), and Pityr- osporum species (cutaneous) were identi?ed in 1 patient each (...) patient-year to 0.4 per 100 patient-years. 21,27 Amulticenterstudyat15transplantcentersin the United States suggested that the cumulative incidence of IFD after heart transplantation was 3.4% during the?rst year. 26 Candida species accounted for 49% of the infections, and Aspergillus species accounted for 23%. More than 50% of the infectionsoccurredinthe?rst90days. 26 Overall,IFDafterheart transplantation is rare; when it occurs, it is usually during the ?rstyearaftertransplant

2015 International Society for Heart and Lung Transplantation

190. The Antimicrobial and Wound Healing Potential of <i>Opuntia ficus indica L. inermis</i> Extracted Oil from Tunisia. (Full text)

of a reference drug Esth'Elle Pharma Cicaplaie cream (reference group), and 0.6 μl/mm2 of OFI seed oil (OFI oil group). The healing process was monitored daily and the percentage of wound contraction was calculated. A histological study was carried on skin biopsies.The extracted oil has shown an interesting antimicrobial effect on Enterobacter cloacae, antiyeast effect against Candida parapsilosis and Candida sake, and antifungal activity against three opportunistic cutaneous molds (Penicillium, Aspergillus (...) , and Fusarium). Moreover, OFI oil has shown a good wound healing effect. It prevents cutaneous infections and reduces the reepithelialization phase.OFI extracted oil has in vitro antimicrobial/fungal properties and in vivo wound healing activity. It seems to be efficient in the treatment of cutaneous infections and the promoting of the scarring process.

2019 Evidence-based Complementary and Alternative Medicine (eCAM) PubMed abstract

191. Skin changes in the obese patient. (Abstract)

manifestations related to obesity include acanthosis nigricans, acrochordons, keratosis pilaris, striae distensae, cellulite, and plantar hyperkeratosis. Obesity has metabolic effects, such as causing hyperandrogenism and gout, which in turn are associated with cutaneous manifestations. Furthermore, obesity is associated with an increased incidence of bacterial and Candida skin infections, as well as onychomycosis, inflammatory skin diseases, and chronic dermatoses like hidradenitis suppurativa, psoriasis

2019 Journal of American Academy of Dermatology

195. Paronychia - acute

features include: Pain and swelling at the base of the fingernail. Localized pain and tenderness of the nail folds. Red, tender, and swollen lateral and/or proximal nail folds often with a visible collection of pus. Conditions that may resemble paronychia include cutaneous candidiasis, acute contact dermatitis, staphylococcal whitlow, finger-tip injuries, insect bites, fungal nail infections, herpetic whitlow, cancer (for example melanoma or squamous cell carcinoma), psoriasis, Reiter syndrome (...) for recommendation Typical symptoms of acute paronychia This information is based on expert opinion in review articles [ ; ; ; ]. Findings on examination This information is based on expert opinion in review articles [ ; ; ; ]. Digital pressure test The guidance on how to carry out a digital pressure test to assess for early infection is based on expert opinion in a review article [ ]. Differential diagnosis What else could it be? Conditions that may resemble paronychia include: Cutaneous candidiasis. Acute

2017 NICE Clinical Knowledge Summaries

196. Pruritus vulvae

topics on and . For more information on the investigation of general pruritus, see the CKS topic on . Vaginal swabs for: Candida sp. — swabs can be considered in all women, as there may be little or no discharge with chronic vulvovaginal candidiasis. For more information, see the CKS topic on . Other infections, if suspected, such as bacterial vaginosis or trichomoniasis. For more information, see the CKS topic on . Referral for patch testing — rarely required. If an allergic contact dermatitis (...) to occur in approximately 0.5% of the Western European and American population — in vulval clinics, it affects around 10–35% of people. Lichen sclerosus is estimated to occur in 1 in 300–1000 women. It is estimated that up to 75% of women will be affected by vulvovaginal candidiasis at least once in their lifetime and that 10% of women will see a doctor for persistent vulval itch at some time in their lives. [ ; ; ; ; ] Prognosis What is the prognosis? The prognosis of pruritus vulvae depends

2017 NICE Clinical Knowledge Summaries

197. ISOLATED CONGENITAL NAIL CANDIDIASIS: REPORT OF 6 CASES. (Abstract)

ISOLATED CONGENITAL NAIL CANDIDIASIS: REPORT OF 6 CASES. Congenital candidal infection usually presents as skin rash but it can also affect skin appendages. Nail involvement in congenital candidiasis is rare and has been usually associated with cutaneous lesions. We report 6 cases of congenital candidiasis limited to nail plates that had favorable outcome.

2010 Pediatric Infectious Dsease Journal

198. Zelboraf - vemurafenib

-protein kinase B-Raf BRAFV600 Codon 600 position of BRAF gene, site of oncogenic mutations BRAFwt Wild-type BRAF gene CI Confidence interval CL/F Apparent clearance in blood after oral administration, calculated as Dose/ AUC0- 8 after a single dose or Dose/AUC0- t at steady state after repeated administration C min Pre-dose trough blood concentration in a dosing interval CR Complete response CRC Colorectal Cancer CT Computed tomography cuSCC Cutaneous squamous cell carcinoma CV Constant volume CYP (...) . sativus, L. lycopersicum OECD 208 NOEC 638 mg/kg shoot weight and length; normalised to 2% o.c. Earthworm, Chronic Test E. fetida OECD 222 NOEC = 833 mg/kg survival, growth, reproduction; normalised to 2% o.c. Collembola, Reproduction Test F. candida ISO 11267 NOEC = 833 mg/kg mortality and reproduction; normalised to 2% o.c. Sediment dwelling organism C. riparius OECD 218 NOEC 2381 mg/kg dw normalised to 10% o.c. Sediment dwelling organism L. variegatus OECD 225 NOEC 1157 mg/kg dw normalised to 10

2012 European Medicines Agency - EPARs

199. Adcetris (brentuximab vedotin)

terminology criteria for adverse events CTCL cutaneous T cell lymphoma CV coefficient of variance CYP cytochrome P450 Da Dalton DCHA Dicyclohexylamine DDI Drug drug interaction DHAOx dexamethasone, high-dose cytarabine, and oxaliplatin DHFR Dihydrofolate Reductase DIPEA N,N-Diisopropylethylamine DLT Dose limiting toxicity DMSO Dimethyl Sulphoxide DO Dissolved Oxygen Adcetris CHMP assessment report Rev10.11 Page 4/102 DoR duration of response DP Drug Product DS drug substance DSC Differential Scanning (...) , including stem cell transplantation, have an estimated median survival of less than 3 years. Gains are limited to disease free survival, but usually no overall survival gains are achieved (Horning et al, 2008). Anaplastic large cell lymphoma (ALCL) is an aggressive non-Hodgkin lymphoma of T-cell origin. There are two distinct forms, systemic ALCL and a primarily cutaneous form. ALCL accounts for 2-8% of all T- cell lymphomas. CD30 is invariably expressed on the surface of ALCL cells. The clinical course

2012 European Medicines Agency - EPARs

200. Alogliptin and alogliptin/pioglitazone

) 43 Table 8. Deaths by SOC (controlled phase 2 and 3 studies) 45 Table 9. SAEs reported by =0.1% of subjects in any group in the 2011 and 2012 resubmissions 46 Table 10. AEs leading to discontinuation reported by =0.1% of subjects in any group in the 2011 and 2012 resubmissions 48 Table 11. Primary MACE composite (controlled phase 2 and 3 studies) 49 Table 12. Summary of narrow scope hypersensitivity AEs (Controlled phase 2 and 3 studies) 49 Table 13. AEs in the severe cutaneous drug reactions (...) Medical Dictionary for Regulatory Activities Met or M Metformin NAI No action indicated MI Myocardial infarction MTD Maximum tolerated dose MMRM Mixed model repeat measures NDA New drug application NME New molecular entity NYHA New York Heart Association OPDP Office of Prescription Drug Promotion OSE Office of Surveillance and Epidemiology OSI Office of Scientific Investigation PCDR Potential cutaneous drug reaction PD Pharmacodynamics PDCO EMA’s pediatric committee PeRC Pediatric Review Committee PI

2012 FDA - Drug Approval Package

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>